PARVB: A Promising Drug Target and Biomarker for HIV-1 and Cancer Treatment

Target Name: PARVB

NCBI ID: G29780

PARVB

PARVB: A Promising Drug Target and Biomarker for HIV-1 and Cancer Treatment

PARVB (Parvavirinalab) is a drug target and a biomarker for treating various diseases, including HIV, hepatitis, and cervical cancer. PARVB is a non-nucleosidic inhibitor of the viral replication process of human immunodeficiency virus (HIV). It works by inhibiting the activity of the reverse transcription enzyme (RTC), which is essential for the production of new viral particles that can infect and replicate in the host cells.

PARVB has been shown to be highly effective in preclinical studies in treating HIV-1 infection. Studies have shown that PARVB can completely suppress the replication of HIV-1 virus in a variety of cell types, including CD4+ T cells, the most common type of HIV-1 host cells. The drug has also been shown to be effective in animal models of HIV-1 infection, leading to the potential for human clinical trials.

PARVB has also been shown to be a potential biomarker for measuring the effectiveness of HIV treatment. Studies have shown that levels of PARVB in the blood can be correlated with the levels of HIV-1 virus in the body, providing a sensitive and reliable method for monitoring the effectiveness of HIV treatment. This has the potential to improve the accuracy and effectiveness of antiretroviral therapy (ART), which is currently the standard treatment for HIV-1 infection.

In addition to its potential as a drug target and biomarker, PARVB also has potential as a therapeutic approach for treating other diseases. The viral replication process is also involved in the development of certain types of cancer, including cervical cancer. Therefore, inhibiting the replication The process of viruses, such as HIV, may also be a potential approach for treating certain types of cancer.

PARVB is currently being investigated in a variety of clinical trials for the treatment of HIV-1 infection and certain types of cancer. While the drug is still in the early stages of development, the potential for PARVB to become a valuable drug or biomarker for treating HIV-1 infection and certain types of cancer is significant. With further research and development, PARVB has the potential to make a significant impact on the treatment of HIV-1 disease and certain types of cancer.

Protein Name: Parvin Beta

Functions: Adapter protein that plays a role in integrin signaling via ILK and in activation of the GTPases CDC42 and RAC1 by guanine exchange factors, such as ARHGEF6. Is involved in the reorganization of the actin cytoskeleton and formation of lamellipodia. Plays a role in cell adhesion, cell spreading, establishment or maintenance of cell polarity, and cell migration

The "PARVB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARVB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets